Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Shares Issued (2016 - 2025)

Historic Shares Issued for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $774000.0.

  • Celldex Therapeutics' Shares Issued changed N/A to $774000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 9983.95%. This contributed to the annual value of $432.3 million for FY2024, which is 9993.25% up from last year.
  • Celldex Therapeutics' Shares Issued amounted to $774000.0 in Q3 2025.
  • Celldex Therapeutics' Shares Issued's 5-year high stood at $432.3 million during Q1 2024, with a 5-year trough of -$25000.0 in Q2 2021.
  • Its 5-year average for Shares Issued is $57.7 million, with a median of $280500.0 in 2022.
  • Data for Celldex Therapeutics' Shares Issued shows a peak YoY increase of 6219106.63% (in 2024) and a maximum YoY decrease of 10150.38% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Shares Issued stood at $269.8 million in 2021, then tumbled by 99.48% to $1.4 million in 2022, then skyrocketed by 15322.08% to $215.1 million in 2023, then plummeted by 100.0% to -$2000.0 in 2024, then soared by 38800.0% to $774000.0 in 2025.
  • Its Shares Issued stands at $774000.0 for Q3 2025, versus $63000.0 for Q2 2025 and $202000.0 for Q1 2025.